{"url":"https://newsforagent.com/news/2026-10-18/veradermics-phase-3-304-topline-call","markdown_url":"https://newsforagent.com/news/2026-10-18/veradermics-phase-3-304-topline-call.md","title":"VeraDermics Sets October 19 Call on Phase 3 Hair Loss Data","headline":"VeraDermics to Review Phase 3 '304' Topline Data for VDPHL01 on October 19","description":"VeraDermics will host an October 19, 2026 call on topline results from Part A of its Phase 3 '304' trial of VDPHL01 in more than 500 men.","section":"Research & Clinical Trials","published_at":"2026-10-18T22:51:05+00:00","modified_at":"2026-10-18T22:51:05+00:00","author":"News Desk","key_takeaways":["VeraDermics scheduled an October 19, 2026 call and webcast at 8:00 am ET to review topline results from Part A of its Phase 3 '304' trial of VDPHL01.","The Phase 3 '304' trial enrolled more than 500 males with mild-to-moderate pattern hair loss and measures co-primary endpoints at Month 6.","VDPHL01 is an extended-release oral minoxidil that, if approved, could be the only FDA-approved oral non-hormonal option for pattern hair loss."],"companies":[{"name":"VeraDermics","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000dzo/veradermics","website":"https://www.veradermics.com"}],"source":{"publisher":"TradingView","title":"Veradermics, Incorporated (MANE) Sets Call to Review Phase 3 ‘304’ Topline Data","url":"https://www.tradingview.com/news/tradingview:c47a2891ce4cf:0-veradermics-incorporated-mane-sets-call-to-review-phase-3-304-topline-data/"},"other_sources":[],"tags":["Research & Clinical Trials","VeraDermics"],"body_markdown":"[VeraDermics](https://akta.pro/company-profiles/0000dzo/veradermics) will host a call and webcast on October 19, 2026 at 8:00 am ET to review topline results from Part A of its Phase 3 '304' trial of VDPHL01 in more than 500 males with mild-to-moderate pattern hair loss, [TradingView](https://www.tradingview.com/news/tradingview:c47a2891ce4cf:0-veradermics-incorporated-mane-sets-call-to-review-phase-3-304-topline-data/) reported. The company said the trial's co-primary endpoints at Month 6 are key to the regulatory path and valuation.\n\n## What the Phase 3 '304' Readout Covers\n\nVeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043, according to [company records](https://akta.pro/company-data). The '304' study is a registration-directed trial whose results inform approval odds, and the program spans three Phase 3 trials with a dataset of more than 1,600 patients that could support label breadth.\n\nVDPHL01 is an extended-release minoxidil; if approved, it could be the only FDA-approved oral non-hormonal option. The company said the October 19 session will review topline Part A data, and that endpoint success is key to the regulatory path and valuation.\n\n## VeraDermics' Funding and Study History\n\nVeraDermics raised approximately $414.4 million in a follow-on equity offering in April 2026, substantially expanding the post-IPO capital base to fund Phase 3 completion and pre-launch commercialization, according to akta.pro company records. The same records show the company reported positive topline Phase 2/3 Study 302 results in April 2026, validating the extended-release oral minoxidil mechanism in men with androgenetic alopecia and de-risking the male registration program.\n\nVeraDermics announced the closing of its upsized initial public offering of 17,339,294 shares of common stock at $17.00 per share in February 2026, generating approximately $294.8 million in gross proceeds before deducting underwriting discounts and offering expenses, with the offering including the full exercise of the underwriters' option to purchase additional shares.\n\n## Earlier VeraDermics Milestones\n\nVeraDermics reported positive topline results from its open-label Phase 2 Study 207 for its VDPHL01 program targeting female hair loss in August 2026, noting significant increases in hair count and improved coverage without serious adverse events, Longevity.Technology reported. The same month, VeraDermics reported its second quarter 2026 financial results, highlighting positive Phase 2 data for VDPHL01 and the completion of enrollment in a key Phase 2/3 trial, Gurufocus reported.\n\nIn September 2026, CEO Reid Waldman presented at Citigroup's Biopharma Back to School Summit 2026, detailing the company's development of VDPHL01, the first minoxidil extended-release tablet for pattern hair loss, Seeking Alpha reported.\n\n## What Follows the October 19 Call\n\nThe October 19, 2026 call and webcast at 8:00 am ET will review topline results from Part A of the Phase 3 '304' trial, with co-primary endpoints measured at Month 6.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}